Evidence map›Paper›PMID 33180821›Full record

ArticlePloS one2020

The thromboprotective effect of traditional Chinese medicine Tongji 2 granules is dependent on anti-inflammatory activity by suppression of NF-κB pathways.

Lin Zhou, Stephanie Lapping, Xudong Liao, Yuan Lu, Guangjin Zhou, Keiichiro Matoba, Neelakantan Vasudevan, Lemin Wang, Lalitha Nayak

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Lin ZhouDepartment of Cardiology, Tongji Hospital of Tongji University, Shanghai, China.
Stephanie LappingCase Cardiovascular Research Institute, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States of America.
Xudong LiaoCase Cardiovascular Research Institute, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States of America.
Yuan LuCase Cardiovascular Research Institute, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States of America.
Guangjin ZhouCase Cardiovascular Research Institute, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States of America.
Keiichiro MatobaDivision of Diabetes, Endocrinology, and Metabolism, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.ORCID 0000-0003-0041-0483
Neelakantan VasudevanCase Cardiovascular Research Institute, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States of America.
Lemin WangDepartment of Cardiology, Tongji Hospital of Tongji University, Shanghai, China.
Lalitha NayakDivision of Hematology and Oncology, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States of America.ORCID 0000-0002-9534-3502
University Hospitals of Cleveland · USTongji University · CNJikei University School of Medicine · JP

Funding

Novel approaches to improve prediction of cancer-associated thrombosisU01HL143402 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI KHORANA, ALOK A, MCCRAE, KEITH R. · 2018 to 2022
$4.7M
Role of myeloid KLF2 in antiphospholipid antibody-mediated thrombosisR01HL142647 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI NAYAK, LALITHA · 2018 to 2021
$1.9M
Role of Myeloid Kruppel-like Factor 2 in Vascular ThrombosisK08HL121131 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI NAYAK, LALITHA · 2014 to 2018
$754k
NHLBI NIH HHS K08 HL121131NHLBI NIH HHS R01 HL142647NHLBI NIH HHS U01 HL143402
6 · The paper itself

Abstract

Inflammation is a vital physiological response of the immune system meant to protect against the invasion of pathogens. However, accumulating evidence describes an intimate link between inflammation and thrombosis and cellular elements of the immune system of the immune system such as neutrophils and monocytes/macrophages are emerging as key players in the generation of a prothrombotic milieu suggesting that anti-inflammatory therapy may have a role in the management of thrombosis that is driven by inflammation. Tongji 2 (TJ2) is a traditional Chinese medication manufactured as granules by Tongji hospital of Tongji University (Shanghai, China) with known anti-inflammatory properties. In this study, we examine the effects of TJ2 on inflammation and thrombosis. Our study shows that TJ2 modulates NF-κB activation and thus generates a prominent anti-inflammatory effect. Further, we use mouse models of thrombosis to demonstrate that TJ2 has a beneficial effect in both arterial and venous thrombosis that occurs in the absence of alterations in platelet activation or coagulation.

Indexed as

AnimalsAnti-Inflammatory AgentsCells, CulturedDrugs, Chinese HerbalEndothelial CellsEndothelium, VascularFibrinolytic AgentsHumansMaleMiceMice, Inbred C57BLNF-kappa BRAW 264.7 CellsVenous ThrombosisAnti-Inflammatory AgentsDrugs, Chinese HerbalFibrinolytic AgentsNF-kappa B

Identifiers

PMID33180821
PMCPMC7660536
OpenAlexW3098171959

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.